Biomarker discovery and patient stratification in pancreatic cancer using incomplete multi-omics data

The useful part

by Alejandra Paja-García, Rafael Romero-Becerra, Tero Aittokallio, Alberto López Pancreatic ductal adenocarcinoma (PDAC), with a 12% 5-year survival rate, is the most aggressive type of cancer. Early diagnosis for this pathology is rare, and conventional treatments such as surgery, radio- or chemotherapy, have little to no effect on reducing mortality. Machine learning (ML) approaches could be used to identify biomarkers that help clinicians stratify patients and improve treatment outcomes.

How it works

• However, most ML techniques perform poorly with incomplete data, which is usually the case in real-world settings, often forcing researchers to discard valuable information.
• Comprehensive multi-omics analyses revealed substantial molecular differences between patients in both groups, identified three methylation biomarkers to stratify patients, and highlighted dysregulation in...
• Using an independent cohort, we further demonstrated that both the prognostic value of these subtypes and their underlying biological characteristics are reproducible.
• These results could lead to better stratified treatment regimens to improve the prognosis of PDAC patients.

Details worth keeping

Through a large-scale clustering benchmark including six omics layers, we discovered two novel subgroups with statistically significant differences in survival and recurrence after surgery, particularly within the first two years, when most patient deaths occur, as well as distinct tumor mutational burden.